Published in Curr Heart Fail Rep on December 01, 2009
Cardiac remodeling at the population level--risk factors, screening, and outcomes. Nat Rev Cardiol (2011) 1.43
Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol (2015) 0.88
Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep (2013) 0.82
Short-term ECG recordings for heart rate assessment in patients with chronic atrial fibrillation. Arch Med Sci (2014) 0.82
Management of tachycardia. F1000Prime Rep (2015) 0.75
Myocardial perfusion scintigraphy before and after cardioversion for atrial fibrillation: recovery of quantitative parameters. J Nucl Cardiol (2011) 0.75
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation (2009) 2.06
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99
Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation (2004) 1.73
Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol (2009) 1.72
A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm (2007) 1.61
Safety of sports participation in patients with implantable cardioverter defibrillators: a survey of heart rhythm society members. J Cardiovasc Electrophysiol (2006) 1.53
Implantable cardioverter defibrillators: do women fare worse than men? Gender comparison in the INTRINSIC RV trial. J Cardiovasc Electrophysiol (2009) 1.51
Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm (2008) 1.45
Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int (2007) 1.45
Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med (2003) 1.43
Early versus late atrial fibrillation after atrial flutter ablation. J Interv Card Electrophysiol (2002) 1.42
Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial. Heart Rhythm (2011) 1.38
The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). J Am Coll Cardiol (2013) 1.26
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2015) 1.26
Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 1.15
Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol (2006) 1.13
Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace (2006) 1.09
Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation (2013) 1.04
A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids for Inhibition of Supraventricular Arrhythmias After Cardiac Surgery: The FISH Trial. J Am Heart Assoc (2012) 1.00
Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol (2003) 0.93
Arrhythmias in tako-tsubo syndrome--benign or malignant? Int J Cardiol (2006) 0.92
The dual role of implantable loop recorder in patients with potentially arrhythmic symptoms: a retrospective single-center study. Pacing Clin Electrophysiol (2009) 0.92
High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. Europace (2008) 0.92
Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J (2003) 0.91
HRS/ACCF expert consensus statement on pacemaker device and mode selection. J Am Coll Cardiol (2012) 0.90
Are treatments for vasovagal syncope effective? A meta-analysis. Int J Cardiol (2012) 0.90
Addendum to the clinical competency statement: training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. Heart Rhythm (2005) 0.89
Pericarditis in myasthenia gravis. Cardiol Rev (2004) 0.88
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol (2011) 0.87
Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace (2013) 0.87
Syncope Unit: rationale and requirement - the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society. Europace (2015) 0.84
Protecting the heart of the American athlete: proceedings of the American College of Cardiology Sports and Exercise Cardiology Think Tank October 18, 2012, Washington, DC. J Am Coll Cardiol (2014) 0.83
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol (2017) 0.83
Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol (2012) 0.82
Wide QRS, narrow QRS: what's the difference? J Am Coll Cardiol (2005) 0.82
Delayed maximal response to left cardiac sympathectomy for catecholaminergic polymorphic ventricular tachycardia. Europace (2010) 0.81
Slower heart rates for healthy hearts: time to redefine tachycardia? Circ Arrhythm Electrophysiol (2008) 0.81
Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med (2007) 0.81
Ambulatory ECG monitoring in atrial fibrillation management. Prog Cardiovasc Dis (2013) 0.79
Treatment of PVCs post-myocardial infarction: Will we get fooled again? Heart Rhythm (2009) 0.79
Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev (2011) 0.79
The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation? Thromb Haemost (2015) 0.79
Syncope in congestive heart failure. Cardiol J (2008) 0.78
Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials. Europace (2014) 0.78
Does cardiac resynchronization therapy benefit patients with ischemic and non-ischemic cardiomyopathy similarly? Int J Cardiol (2013) 0.78
What's So Inappropriate About Sinus Tachycardia? J Cardiovasc Electrophysiol (2008) 0.78
Sport and arrhythmias: summary of an international symposium. Eur J Cardiovasc Prev Rehabil (2007) 0.78
Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol. Ann Noninvasive Electrocardiol (2012) 0.77
Update on medical management of atrial fibrillation in the modern era. Heart Rhythm (2009) 0.77
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2015) 0.77
Increased prevalence of atrial fibrillation in the endurance athlete: potential mechanisms and sport specificity. Phys Sportsmed (2014) 0.77
Electrophysiological characterization of cardiac veins in humans. J Interv Card Electrophysiol (2004) 0.77
Do baseline diastolic echocardiographic parameters predict outcome after resynchronization therapy? Results from the PROSPECT trial. Pacing Clin Electrophysiol (2012) 0.77
Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. Prog Cardiovasc Dis (2004) 0.76
The editor's roundtable: medical management of atrial fibrillation. Am J Cardiol (2012) 0.76
Carotid sinus hypersensitivity: disease state or clinical sign of ageing? The need for hard endpoints. Europace (2010) 0.75
Antiarrhythmic effects of statins in heart failure. Heart Fail Clin (2008) 0.75
DAVID II did not slay Goliath. J Am Coll Cardiol (2009) 0.75
Combining ablation of atrial fibrillation with ablation of atrial flutter: are we there yet? J Am Coll Cardiol (2004) 0.75
Ibutilide revisited: stronger and safer than ever. Europace (2009) 0.75
Response. Chest (2014) 0.75
Is the approach to atrial fibrillation ablation becoming more complex and fractionated? Heart Rhythm (2006) 0.75
Advances in the management of atrial fibrillation in congestive heart failure. F1000 Med Rep (2009) 0.75
The "pill-in-the-pocket" approach to atrial fibrillation. N Engl J Med (2005) 0.75
Using omega-3 fatty acids to treat persistent atrial fibrillation: time to fish or cut bait? Heart Rhythm (2011) 0.75
Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena? Indian Pacing Electrophysiol J (2009) 0.75
The ACCF/AHA scientific statement on syncope needs rethinking. J Am Coll Cardiol (2006) 0.75
Electrocardiographic imaging: back to the drawing board? Heart Rhythm (2011) 0.75
Response. Chest (2014) 0.75
The DAVID trial and its implications: where do we go from here? Curr Cardiol Rep (2003) 0.75
Rate control in atrial fibrillation: what approach is best? Curr Cardiol Rep (2004) 0.75
Endovascular procedures for the treatment of autonomic dysfunction. Clin Auton Res (2013) 0.75
Advances in atrial flutter mapping: what goes around comes around. J Cardiovasc Electrophysiol (2004) 0.75
High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth. J Am Coll Cardiol (2002) 0.75
OptiVol fluid index: does an association with ventricular arrhythmias hold water? J Cardiovasc Electrophysiol (2010) 0.75
Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation. Core Evid (2010) 0.75
Implantable defibrillator use for de novo ventricular tachyarrhythmias encountered after cardiac surgery. Pacing Clin Electrophysiol (2002) 0.75
Unusual response to atrial extrastimulus testing. J Cardiovasc Electrophysiol (2002) 0.75
Older persons with diabetes receive fewer inappropriate ICD shocks: results from the INTRINSIC RV trial. J Cardiovasc Transl Res (2010) 0.75
The editor's roundtable: Implantable cardioverter-defibrillators in primary prevention of sudden cardiac death and disparity-related barriers to implementation. Am J Cardiol (2011) 0.75
The impact of atrial prevention and termination therapies on atrial tachyarrhythmia burden in patients receiving a dual-chamber defibrillator for ventricular arrhythmias. J Interv Card Electrophysiol (2004) 0.75
Inadvertent positioning of pacemaker leads in the pericardium. Pacing Clin Electrophysiol (2003) 0.75
Sports and arrhythmias: a report of the International Workshop Venice Arrhythmias 2009. Eur J Cardiovasc Prev Rehabil (2010) 0.75
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol (2017) 0.75
Correlation of noninvasive electrocardiography with invasive electrophysiology in syncope of unknown origin: implications from a large syncope database. Ann Noninvasive Electrocardiol (2009) 0.75
Task Force 9: drugs and performance-enhancing substances. J Am Coll Cardiol (2005) 0.75
Not so innocent bystander(s). Europace (2009) 0.75
Temporary biventricular pacing in a patient with subacute myocardial infarction, cardiogenic shock, and third-degree atrioventricular block. Heart Rhythm (2005) 0.75
Complementary and alternative medicine: the need for data. Cardiol Rev (2003) 0.75
Irregular atrial activation during atrioventricular nodal reentrant tachycardia: evidence of an upper common pathway. J Cardiovasc Electrophysiol (2003) 0.75